Literature DB >> 28822839

Decreased surface expression of the δ subunit of the GABAA receptor contributes to reduced tonic inhibition in dentate granule cells in a mouse model of fragile X syndrome.

Nianhui Zhang1, Zechun Peng1, Xiaoping Tong1, A Kerstin Lindemeyer2, Yliana Cetina1, Christine S Huang1, Richard W Olsen3, Thomas S Otis4, Carolyn R Houser5.   

Abstract

While numerous changes in the GABA system have been identified in models of Fragile X Syndrome (FXS), alterations in subunits of the GABAA receptors (GABAARs) that mediate tonic inhibition are particularly intriguing. Considering the key role of tonic inhibition in controlling neuronal excitability, reduced tonic inhibition could contribute to FXS-associated disorders such as hyperactivity, hypersensitivity, and increased seizure susceptibility. The current study has focused on the expression and function of the δ subunit of the GABAAR, a major subunit involved in tonic inhibition, in granule cells of the dentate gyrus in the Fmr1 knockout (KO) mouse model of FXS. Electrophysiological studies of dentate granule cells revealed a marked, nearly four-fold, decrease in tonic inhibition in the Fmr1 KO mice, as well as reduced effects of two δ subunit-preferring pharmacological agents, THIP and DS2, supporting the suggestion that δ subunit-containing GABAARs are compromised in the Fmr1 KO mice. Immunohistochemistry demonstrated a small but statistically significant decrease in δ subunit labeling in the molecular layer of the dentate gyrus in Fmr1 KO mice compared to wildtype (WT) littermates. The discrepancy between the large deficits in GABA-mediated tonic inhibition in granule cells in the Fmr1 KO mice and only modest reductions in immunolabeling of the δ subunit led to studies of surface expression of the δ subunit. Cross-linking experiments followed by Western blot analysis demonstrated a small, non-significant decrease in total δ subunit protein in the hippocampus of Fmr1 KO mice, but a four-fold decrease in surface expression of the δ subunit in these mice. No significant changes were observed in total or surface expression of the α4 subunit protein, a major partner of the δ subunit in the forebrain. Postembedding immunogold labeling for the δ subunit demonstrated a large, three-fold, decrease in the number of symmetric synapses with immunolabeling at perisynaptic locations in Fmr1 KO mice. While α4 immunogold particles were also reduced at perisynaptic locations in the Fmr1 KO mice, the labeling was increased at synaptic sites. Together these findings suggest that, in the dentate gyrus, altered surface expression of the δ subunit, rather than a decrease in δ subunit expression alone, could be limiting δ subunit-mediated tonic inhibition in this model of FXS. Finding ways to increase surface expression of the δ subunit of the GABAAR could be a novel approach to treatment of hyperexcitability-related alterations in FXS.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dentate gyrus; Fmr1 gene; Fragile X mental retardation protein; Fragile X syndrome; GABA receptor; Tonic inhibition

Mesh:

Substances:

Year:  2017        PMID: 28822839      PMCID: PMC5612918          DOI: 10.1016/j.expneurol.2017.08.008

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  87 in total

1.  Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety.

Authors:  Jamie L Maguire; Brandon M Stell; Mahsan Rafizadeh; Istvan Mody
Journal:  Nat Neurosci       Date:  2005-05-15       Impact factor: 24.884

Review 2.  Altered expression of δGABAA receptors in health and disease.

Authors:  Paul D Whissell; Irene Lecker; Dian-Shi Wang; Jieying Yu; Beverley A Orser
Journal:  Neuropharmacology       Date:  2014-08-13       Impact factor: 5.250

Review 3.  Clinical Potential of Neurosteroids for CNS Disorders.

Authors:  Doodipala Samba Reddy; William A Estes
Journal:  Trends Pharmacol Sci       Date:  2016-05-05       Impact factor: 14.819

4.  Epilepsy and EEG findings in males with fragile X syndrome.

Authors:  S A Musumeci; R J Hagerman; R Ferri; P Bosco; B Dalla Bernardina; C A Tassinari; G B De Sarro; M Elia
Journal:  Epilepsia       Date:  1999-08       Impact factor: 5.864

5.  Molecular basis for the high THIP/gaboxadol sensitivity of extrasynaptic GABA(A) receptors.

Authors:  Pratap Meera; Martin Wallner; Thomas S Otis
Journal:  J Neurophysiol       Date:  2011-07-27       Impact factor: 2.714

6.  Ethanol promotes clathrin adaptor-mediated endocytosis via the intracellular domain of δ-containing GABAA receptors.

Authors:  Claudia Gonzalez; Stephen J Moss; Richard W Olsen
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

7.  Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus.

Authors:  K A Wafford; M B van Niel; Q P Ma; E Horridge; M B Herd; D R Peden; D Belelli; J J Lambert
Journal:  Neuropharmacology       Date:  2008-08-13       Impact factor: 5.250

Review 8.  The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders.

Authors:  Sien Braat; R Frank Kooy
Journal:  Neuron       Date:  2015-06-03       Impact factor: 17.173

9.  Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABAA receptors.

Authors:  Armen M Abramian; Eydith Comenencia-Ortiz; Amit Modgil; Thuy N Vien; Yasuko Nakamura; Yvonne E Moore; Jamie L Maguire; Miho Terunuma; Paul A Davies; Stephen J Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

10.  Modulation of neurosteroid potentiation by protein kinases at synaptic- and extrasynaptic-type GABAA receptors.

Authors:  Joanna M Adams; Philip Thomas; Trevor G Smart
Journal:  Neuropharmacology       Date:  2014-09-30       Impact factor: 5.250

View more
  17 in total

Review 1.  Cortical interneurons in autism.

Authors:  Anis Contractor; Iryna M Ethell; Carlos Portera-Cailliau
Journal:  Nat Neurosci       Date:  2021-11-29       Impact factor: 24.884

2.  FMRP regulates GABAA receptor channel activity to control signal integration in hippocampal granule cells.

Authors:  Pan-Yue Deng; Ajeet Kumar; Valeria Cavalli; Vitaly A Klyachko
Journal:  Cell Rep       Date:  2022-05-17       Impact factor: 9.995

3.  Spontaneous seizures in adult Fmr1 knockout mice: FVB.129P2-Pde6b+Tyrc-chFmr1tm1Cgr/J.

Authors:  Jessica L Armstrong; Tanishka S Saraf; Omkar Bhatavdekar; Clinton E Canal
Journal:  Epilepsy Res       Date:  2022-03-08       Impact factor: 2.991

4.  An Astrocytic Influence on Impaired Tonic Inhibition in Hippocampal CA1 Pyramidal Neurons in a Mouse Model of Rett Syndrome.

Authors:  Qiping Dong; Jason Kim; Linh Nguyen; Qian Bu; Qiang Chang
Journal:  J Neurosci       Date:  2020-07-02       Impact factor: 6.167

Review 5.  Channelopathies in fragile X syndrome.

Authors:  Pan-Yue Deng; Vitaly A Klyachko
Journal:  Nat Rev Neurosci       Date:  2021-04-07       Impact factor: 34.870

Review 6.  Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model.

Authors:  Richard W Olsen; Jing Liang
Journal:  Mol Brain       Date:  2017-09-20       Impact factor: 4.041

Review 7.  Impaired GABA Neural Circuits Are Critical for Fragile X Syndrome.

Authors:  Fei Gao; Lijun Qi; Zhongzhen Yang; Tao Yang; Yan Zhang; Hui Xu; Huan Zhao
Journal:  Neural Plast       Date:  2018-10-03       Impact factor: 3.599

Review 8.  Molecular Biomarkers in Fragile X Syndrome.

Authors:  Marwa Zafarullah; Flora Tassone
Journal:  Brain Sci       Date:  2019-04-27

9.  Development of GABAergic Inputs Is Not Altered in Early Maturation of Adult Born Dentate Granule Neurons in Fragile X Mice.

Authors:  Christine L Remmers; Anis Contractor
Journal:  eNeuro       Date:  2018-12-03

10.  Combination Therapy in Fragile X Syndrome; Possibilities and Pitfalls Illustrated by Targeting the mGluR5 and GABA Pathway Simultaneously.

Authors:  Shimriet Zeidler; Helen de Boer; Renate K Hukema; Rob Willemsen
Journal:  Front Mol Neurosci       Date:  2017-11-07       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.